View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

JP Morgan tops GlobalData’s ranking of financial advisers in healthcare M&As

JP Morgan led the pack of the top 20 global financial advisers for the healthcare industry in the latest M&A league table for Q2 2018, compiled by leading data analytics companyGlobalData.

By GlobalData Healthcare

JP Morgan led the pack of the top 20 global financial advisers for the healthcare industry in the latest M&A league table for Q2 2018, compiled by leading data analytics company GlobalData.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Driven by the $80bn Takeda-Shire deal, the biggest transaction in the quarter for any sector, the bank topped the league table in terms of both value and volume, with $99.2bn and 11 deals, respectively. The same deal helped Goldman Sachs, Citi, Morgan Stanely and Evercoreto complete the top five slots.

According to GlobalData, which uses its tracking of all mergers and acquisitions, private equity, venture capital and asset transaction activity around the world to compile the league table, JP Morgan was ranked third in its global league table of financial advisers released recently.

Global Healthcare deals market Q2 2018

The overall global Healthcare deals market has seen a more than double jump in value from $70.3bn in Q2 2017 to $166.6bn in Q2 2018, but slipped marginally in volumes by 9% from 923 to 840 respectively during the quarters in review.

All announced deals count towards the league table total complied by GlobalData.

A few financial advisers such as Dyal Co, Goetzpartners, PJT Partners made it to the top 20 list, despite featuring in just one deal each during Q2 2018.

Sullivan tops legal advisers ranking

US law firm Sullivan & Cromwell grabbed the top rank in the healthcare league table of top 20 legal advisers for the second quarter of 2018. The company also came first in the global league table of top 20 legal advisers released by GlobalData recently.

Even though Sullivan and Davis Polk were involved in four deals each during the reporting period, Sullivan edged past Davis Polk to lead the table riding on the back of deals involving Novartis and Bayer.

In terms of volumes, Latham & Watkins, Kirkland & Ellis and Cooley stood in top three ranks with 11, nine and eight deals, respectively. These three firms were ranked 3rd, 11th and 13th respectively in value terms.

GlobalData Financial Deals Analyst Prakhar Baghmar said: “Q2 2018 has been an eventful period for global healthcare deal activity, with about a 137% jump in deal value as compared with Q2 2017. At US$80bn, the Takeda-Shire deal accounted for close to half of the total healthcare deal value in the quarter and also played a key role in deciding the top rankings for both league tables.”

GlobalData is the parent company of the Verdict Network, which includes Pharmaceutical Technology and Verdict Medical Devices.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology